SIGA - SIGA Technologies, Inc.

Other OTC - Other OTC Delayed Price. Currency in USD

SIGA Technologies, Inc.

660 Madison Avenue
Suite 1700
New York, NY 10065
United States

Full Time Employees36

Key Executives

Dr. Eric A. Rose M.D.2.22MN/A66
Dr. Phillip Louis Gomez III, Ph.D.162.5kN/A50
Mr. Daniel J. Luckshire1.68MN/A46
Dr. Dennis E. Hruby Ph.D.1.98MN/A65
Ms. Robin E. Abrams J.D.916.89kN/A53
Amounts are as of December 31, 2016 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


SIGA Technologies, Inc. engages in the development and commercialization of solutions for unmet medical needs and biothreats in the United States. Its lead product is TPOXX, an orally administered antiviral drug for treating orthopoxvirus infections. SIGA Technologies, Inc. was founded in 1995 and is headquartered in New York, New York.

Corporate Governance

SIGA Technologies, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.